1.上海中医药大学(上海 201203)
2.四川省中医药转化医学中心(四川 成都 610041)
周冰霞,女,硕士研究生,主要从事新药研发工作
刘梅,副研究员,硕士研究生导师; E-mail: liumeiy@aliyun.com
扫 描 看 全 文
周冰霞,华桦,刘梅.肿节风抗肿瘤临床疗效及其作用机制研究进展[J].上海中医药杂志,2023,57(11):85-89.
ZHOU Bingxia,HUA Hua,LIU Mei.Research progress in anti⁃tumor clinical efficacy and mechanism of action of Sarcandrae Herba[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(11):85-89.
周冰霞,华桦,刘梅.肿节风抗肿瘤临床疗效及其作用机制研究进展[J].上海中医药杂志,2023,57(11):85-89. DOI: 10.16305/j.1007-1334.2023.2305090.
ZHOU Bingxia,HUA Hua,LIU Mei.Research progress in anti⁃tumor clinical efficacy and mechanism of action of Sarcandrae Herba[J].Shanghai Journal of Traditional Chinese Medicine,2023,57(11):85-89. DOI: 10.16305/j.1007-1334.2023.2305090.
综述肿节风抗肿瘤临床疗效及其作用机制的研究进展。临床研究表明,肿节风具有良好的抗肿瘤作用,配合化学疗法和放射治疗应用可发挥增效减毒的作用。体内外实验研究发现,肿节风对消化道肿瘤、呼吸道肿瘤、乳腺癌等具有细胞毒性和肿瘤抑制作用。其抗肿瘤作用机制主要与抑制细胞增殖、诱导细胞凋亡、抑制细胞端粒酶活性、抑制细胞侵袭和迁移等有关。
This article reviews the research progress in the clinical efficacy and mechanism of action of Zhongjiefeng (Sarcandrae Herba) in anti-tumor treatment. Clinical studies have shown that Zhongjiefeng (Sarcandrae Herba) has a strong anti-tumor effect and can enhance the efficacy and reduce toxicity when used in combination with chemotherapy and radiation therapy. ,In vitro, and ,in vivo, studies have shown that Zhongjiefeng(Sarcandrae Herba) has cytotoxic and tumor inhibitory effects on digestive tract tumors, respiratory tract tumors, breast cancer, etc. Its anti-tumor mechanism is primarily associated with inhibiting cell proliferation, inducing cell apoptosis, inhibiting telomerase activity, and suppressing cell invasion and migration.
肿节风抗肿瘤中药临床疗效作用机制研究进展
Sarcandrae Herbaanti-tumortraditional Chinese herbal medicineclinical efficacymechanism of actionresearch progress
国家药典委员会. 中华人民共和国药典(2020年版):一部[M]. 北京:中国医药科技出版社,2020: 233-234.
LI C, WEN R, LIU D, et al. Assessment of the potential of Sarcandra glabra(Thunb.) Nakai. in treating ethanol-induced gastric ulcer in rats based on metabolomics and network analysis[J]. Frontiers Pharmacol, 2022, 13: 810344.
JIN L, GUAN X, LIU W, et al. Characterization and antioxidant activity of a polysaccharide extracted from Sarcandra glabra[J]. Carbohyd Polym, 2012, 90(1): 524-532.
MARWAN ALMOSNID N, ZHOU X, JIANG L, et al. Evaluation of extracts prepared from 16 plants used in Yao ethnomedicine as potential anticancer agents[J]. J Ethnopharmacol, 2018, 211: 224-234.
秦亚秋,黄天擎,刘鄂湖. 草珊瑚化学成分及活性研究概述[J]. 广东化工,2023, 50(1): 94-95, 91.
杨秀伟. 草珊瑚属药用植物的生物活性物质基础[J]. 中国现代中药,2017, 19(2): 155-164.
任博雪,任欢欢,陈小宇,等. 迷迭香酸对乳腺癌MDA-MB-231细胞增殖、凋亡和迁移能力的影响[J]. 天然产物研究与开发,2018, 30(8): 1300-1305, 1333.
李晓,李灿楦,林晏廷,等. 基于网络药理学的肿节风治疗前列腺癌的作用机制探讨[J]. 现代药物与临床,2021, 36(7): 1354-1360.
韩倩,武晓林. 肿节风化学成分和药理作用研究进展[J]. 吉林农业,2017(8): 63-64.
GUO X, SHEN L, TONG Y, et al. Antitumor activity of caffeic acid 3,4-dihydroxyphenethyl ester and its pharmacokinetic and metabolic properties[J]. Phytomedicine, 2013, 20(10): 904-912.
SUN X, ZHAO Q, SI Y, et al. Bioactive structural basis of proteoglycans from Sarcandra glabra based on spectrum-effect relationship[J]. J Ethnopharmacol, 2020, 259: 112941.
李昊泽,周晶,李琦,等. 中西医结合疗法防治肿瘤复发转移的优势及展望[J]. 上海中医药杂志,2022, 56(2): 91-95.
姜伶,李景辉. 中药肿节风的抗肿瘤作用研究进展[J]. 中国执业药师,2014, 11(4): 29-31, 35.
宋朝阳. 肿节风注射液联合阿帕替尼治疗晚期胃癌的临床研究[J]. 现代药物与临床,2017, 32(6): 1114-1117.
李东仁,王花利. 肿节风注射液联合DCF方案治疗晚期胃癌的不良反应及疗效观察[J]. 内蒙古中医药,2013, 32(21): 71-72.
董媛,张莉莉,史丽娜,等. 肿节风注射液辅助治疗晚期食道癌的疗效及对患者血清VEGF、S100A4水平的影响[J]. 现代生物医学进展,2019, 19(19): 3712-3715, 3634.
刘军,陈思洋,曹德根. 肿节风分散片联合常规化疗对非小细胞肺癌胸腔镜手术患者康复的影响[J]. 新中医,2022, 54(14): 143-146.
覃玉桃,王仁生,马姗姗,等. 肿节风结合PF方案治疗鼻咽癌的临床疗效观察[J]. 广西医学,2013, 35(10): 1317-1318, 1326.
陆颖,黄东宁,李桂生. 肿节风防治局部晚期鼻咽癌放射治疗后口干的临床研究[J]. 中国肿瘤临床与康复,2013, 20(9): 980-982.
黄东宁,黄海欣,陆颖. 肿节风联合放化疗治疗局部晚期鼻咽癌的临床观察[J]. 中国中西医结合杂志,2013, 33(4): 456-458.
司珂珂,吴瑞波,陈东珠,等. 肿节风注射液对人肝癌细胞株Bel-7404的抑制作用[J]. 右江民族医学院学报,2012, 34(2): 150-152.
罗艳红,韦永福,李婷,等. 肿节风注射液对人肝癌细胞株HepG2凋亡的影响[J]. 广东医学,2015, 36(9): 1340-1342.
SHEN J, ZHU X, WU Z, et al. Uvangoletin, extracted from Sarcandra glabra, exerts anticancer activity by inducing autophagy and apoptosis and inhibiting invasion and migration on hepatocellular carcinoma cells[J]. Phytomedicine, 2022, 94: 153793.
朱晓莹,李韬,李盛毅,等. 肿节风复方含药血清对肝癌HepG2细胞增殖、端粒酶及凋亡的影响[J]. 中国实验方剂学杂志,2014, 20(2): 109-112.
ZENG Y, LIU J, ZHANG Q, et al. Sarcandra glabrathe traditional uses, phytochemistry and pharmacology of (Thunb.) Nakai, a Chinese herb with potential for development: Review[J]. Front Pharmacol, 2021, 12: 652926.
何志坚,钟睿,刘海云. 肿节风注射液联合5-Fu对人胃癌细胞MGC-803增殖和凋亡的影响[J]. 实用癌症杂志,2014, 29(10): 1205-1207.
DONG A, FANG Y, ZHANG L, et al. Caffeic acid 3,4-dihydroxy-phenethyl ester induces cancer cell senescence by suppressing twist expression[J]. J Pharmacol Exp Ther, 2011, 339(1): 238-247.
周仕轶,丁维俊,张蜀武. 肿节风对人前列腺癌DU-145细胞增殖和凋亡的影响[J]. 辽宁中医杂志,2012, 39(1): 172-175.
李宏,庄海林,林俊锦,等. 肿节风中迷迭香酸成分对乳腺癌细胞增殖、迁移能力及凋亡相关基因表达影响[J]. 中国中药杂志,2018, 43(16): 3335-3340.
李宏,陈菁,李丹,等. 异嗪皮啶对人乳腺癌干细胞凋亡相关基因Bcl-2与Caspase家族表达的影响[J]. 中国临床药理学与治疗学,2018, 23(8): 886-892.
JIA J, YANG M, CHEN Y, et al. Inducing apoptosis effect of caffeic acid 3,4-dihydroxy-phenethyl ester on the breast cancer cells[J]. Tumour Bio, 2014, 35(12): 11781-11789.
陈宇燕,谢强,李宗禹,等. 肿节风分散片对非小细胞肺癌增殖的影响及其分子机制的研究[J]. 齐齐哈尔医学院学报,2018, 39(22): 2626-2630.
陈宇燕. 乳酸和中药肿节风影响非小细胞肺癌增殖的分子机制研究[D]. 芜湖:皖南医学院,2019.
伍振辉,张大玲,袁秋全,等. 基于化学成分药理作用及网络药理学的肿节风质量标志物预测分析[J]. 中国现代中药,2023, 25(5): 1113-1124.
谢雅,杨关根,裘建明,等. 肿节风诱导人结肠癌HCT-8细胞凋亡的体外实验研究[J]. 医药论坛杂志,2018, 39(10): 10-13,16.
谢雅. 肿节风诱导人结肠癌HCT-8细胞凋亡的体内外实验研究[D]. 杭州:浙江中医药大学,2013.
冀艳花,朱学军,吴洁. 肿节风注射液对小鼠T细胞淋巴瘤EL-4细胞的体内外实验研究[J]. 中药新药与临床药理,2015, 6(4): 456-460.
ZHANG Z, LIU W, ZHENG Y, et al. SGP-2, an acidic polysaccharide from Sarcandra glabra, inhibits proliferation and migration of human osteosarcoma cells[J]. Food Funct, 2014, 5(1): 167-175.
ZHANG Z, ZHENG Y, ZHU R, et al. The ERK/eIF4F/Bcl-XL pathway mediates SGP-2 induced osteosarcoma cells apoptosis in vitro and in vivo[J]. Cancer Lett, 2014, 352(2): 203-213.
冀艳花,朱学军,吴洁. 肿节风抗肿瘤作用及其机制的研究进展[J]. 中医药导报,2016, 22(9): 44-46, 55.
陈耿标,陈锦丽,刘映芬. 异嗪皮啶对肝癌患者MMP-7表达水平和癌细胞侵袭能力的影响[J]. 白求恩医学杂志,2016, 14(2): 148-151.
0
浏览量
0
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构